Tag: Compass Pathways - Page 9 - Psychedelic Alpha

Read more about the article COMPASS Pathways joins the Psychiatry Consortium in a collaboration to accelerate drug discovery in mental health care

COMPASS Pathways joins the Psychiatry Consortium in a collaboration to accelerate drug discovery in mental health care

Post published:November 9, 2020
Post category:Press Release

Read more about the article COMPASS Pathways plc to ring Nasdaq Stock Exchange opening bell in celebration of its successful $146.6 million IPO

COMPASS Pathways plc to ring Nasdaq Stock Exchange opening bell in celebration of its successful $146.6 million IPO

Post published:October 26, 2020
Post category:Press Release

Read more about the article Phase 2 Clinical Trial to Evaluate Safety and Efficacy of Psilocybin in Cancer Patients with Major Depressive Disorder

Phase 2 Clinical Trial to Evaluate Safety and Efficacy of Psilocybin in Cancer Patients with Major Depressive Disorder

Post published:October 22, 2020
Post category:Clinical Trials News

Read more about the article COMPASS Pathways Closes $147 million IPO

COMPASS Pathways Closes $147 million IPO

Post published:September 22, 2020
Post category:Press Release

Read more about the article Compass Pathways IPO to Begin Trading 18th September on Nasdaq: CMPS

Compass Pathways IPO to Begin Trading 18th September on Nasdaq: CMPS

Post published:September 18, 2020
Post category:News

Read more about the article Compass Pathways Seeks to Raise $100 million via Nasdaq IPO

Compass Pathways Seeks to Raise $100 million via Nasdaq IPO

Post published:September 15, 2020
Post category:News

Read more about the article Compass Pathways Files for U.S. IPO, to list on Nasdaq

Compass Pathways Files for U.S. IPO, to list on Nasdaq

Post published:August 29, 2020
Post category:News

Read more about the article Mental Health Care Company COMPASS Pathways Strengthens Leadership Team With Appointment of Trevor Mill as Chief Development Officer

Mental Health Care Company COMPASS Pathways Strengthens Leadership Team With Appointment of Trevor Mill as Chief Development Officer

Post published:June 23, 2020
Post category:Press Release

Read more about the article UBS Private Markets Newsletter Features ATAI Guest Piece

UBS Private Markets Newsletter Features ATAI Guest Piece

Post published:May 18, 2020
Post category:News

Read more about the article New York Times runs an article on VC interest in psychedelic medicines, including psilocybin

New York Times runs an article on VC interest in psychedelic medicines, including psilocybin

Post published:March 6, 2020
Post category:News

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.